Drug Profile
Rocatinlimab - Kyowa Kirin
Alternative Names: AMG-451; KHK-4083Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer Amgen; Kyowa Kirin
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis
- Suspended Ulcerative colitis
Most Recent Events
- 15 Feb 2024 Amgen initiates a phase I trial for Atopic dermatitis (In Volunteers) (SC, Injection), in the US (NCT06268860)
- 15 Feb 2024 Amgen plans to initiate a phase I bioavailability trial (In Volunteers) in February 2024 (SC) (NCT06268860)
- 06 Feb 2024 Amgen plans a phase II study in Asthma in H1 2024